The DOI matches its Crossref record; 80 of the 86 references it cites were found in a registry or an index; 22 of the 33 sources its claims cite were checked for support.
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Open accessAbstract
Direct targeting of the KRAS-G12C –mutant protein using covalent inhibitors (G12Ci) acts on human non–small cell lung cancer (NSCLC). However, drug resistance is an emerging concern in this approach. Here, we show that MRTX849, a covalent inhibitor targeting the KRAS-G12C mutation, leads to the reactivation of the mitogen-activated protein kinase signaling pathway in MRTX849-resistant NSCLC and pancreatic ductal adenocarcinoma. A genome-wide CRISPR screen revealed that the adenosine triphosphate binding cassette transporter ABCC1 mediates MRTX849 resistance. Functional studies demonstrated that the transcription factor JUN drives ABCC1 expression, resulting in multidrug resistance. An unbiased drug screen identified the tyrosine kinase inhibitor dasatinib that potentiates MRTX849 efficacy by inhibiting SRC-dependent JUN activation, avoiding multidrug resistance and tumor suppression in vitro as well as in suitable preclinical mouse models and patient-derived organoids. SRC inhibitors (DGY-06-116, dasatinib, and bosutinib) also exhibit synergistic effects with MRTX849 in eliminating various tumor cell lines carrying KRAS-G12C mutations. Thus, SRC inhibitors amplify the therapeutic utility of G12Ci.
Overview
CoChat Summary
TL;DR
MRTX849 resistance in KRAS-G12C NSCLC and PDAC reactivates MAPK signaling and up-regulates ABCC1 through SRC-JUN, producing multidrug resistance. SRC inhibitors such as dasatinib, bosutinib, and DGY-06-116 synergize with MRTX849 in resistant cell lines, mouse models, and patient-derived organoids.
Key findings
- MRTX849-resistant MIA PaCa-2R and Calu1R cells had higher MRTX849 IC50 values than parental cells (MIA PaCa-2R = 60.2 μM versus MIA PaCa-2 = 0.13 μM; Calu1R = 19.2 μM versus Calu1 = 2.5 μM), with ERK/MAPK reactivation and reduced intracellular MRTX849 accumulation.
- ABCC1 mediated resistance: ABCC1 knockout or the ABCC1 inhibitor MK-571 sensitized resistant cells to MRTX849, ABCC1 overexpression induced resistance, and ABCC1 up-regulation also conferred gemcitabine resistance.
- JUN drove ABCC1 expression: JUN bound the ABCC1 promoter at positions −501 to −397 and the CCND1 promoter at −1073 to −893; JUN overexpression increased ABCC1 and reduced MRTX849 growth inhibition, while ABCC1 knockout abrogated JUN-induced resistance.
- A screen of 1421 FDA-approved drugs identified 63 drugs targeting 19 kinases that restored MRTX849-mediated growth inhibition; dasatinib was prioritized and synergized with MRTX849 across 11 KRAS-G12C–mutant NSCLC cell lines but not in KRAS-G12D PANC1 or KRAS WT cells. SRC knockdown sensitized resistant cells to MRTX849, and SRC WT or SRC Y530F, but not kinase-dead SRC K298M, induced resistance.
Methods
- MRTX849-resistant Calu1R and MIA PaCa-2R cells were generated by culturing KRAS-G12C–mutant Calu1 and MIA PaCa-2 cells with increasing MRTX849 (100 nM–50,000 nM) for 6 months and maintaining them at 1000 nM; analyses included RNA-seq, CRISPR-Cas9 screen reanalysis, phosphokinase arrays, ChIP, immunoblots, CCK-8, colony formation, LC-MS/MS, RAS-GTP pull-down, and molecular docking.
- Drug screening used 1421 FDA-approved drugs at 10 μM with or without MRTX849 (1 μM) in MIA PaCa-2 and MIA PaCa-2R cells, with synergy assessed by SynergyFinder; validation included KRAS-G12C NSCLC lines, KRAS-G12D PANC1, KRAS WT cells, and patient-derived organoids HCC4300-PDX-ORG and HCC4285-PDX-ORG.
- In vivo studies used subcutaneous MIA PaCa-2/MIA PaCa-2R or Calu1/Calu1R xenografts in nude mice and mKRC.1 syngeneic C57BL/6 mice, treated with MRTX849 alone or combined with dasatinib or bosutinib, with tumor growth, survival, immunohistochemistry, body weight, and organ weights assessed.
Limitations
- The paper states that ABCC1 knockout only partially reversed resistance in MIA PaCa-2R cells, indicating additional resistance mechanisms, and that ABCC1 up-regulation is likely not the sole mechanism of acquired KRAS-G12Ci resistance.
- The paper notes that direct pharmacological inhibition of JUN remains challenging, small-molecule ABCC1 inhibition has failed in clinical trials, and SRC inhibitors are associated with adverse events including bleeding, infection, anemia, thrombocytopenia, diarrhea, edema, pleural effusion, and pulmonary hypertension; bosutinib plus MRTX849 decreased spleen, pancreas, heart, and kidney weights and caused kidney and pancreas histopathology in mice.
- Evident from the text: the findings are preclinical, based on two main resistant cell line models, mouse xenografts/syngeneic models, and organoids, with no clinical validation; resistance mechanisms differed between AMG510 and MRTX849 in some contexts, and gemcitabine plus dasatinib showed toxicity without a significant tumor weight difference versus gemcitabine alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6. Synergistic effect of MRTX849 and dasatinib on tumor suppression in mouse models. (A) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (35 mg/kg, p.o., oral gavage) and dasatinib (35 mg/kg, oral gavage) in MIA PaCa-2/MIA PaCa-2R xenograft models. sc, subcutaneously. (B) The tumor growth was monitored twice per week (n = 8 to 10 tumor; **P < 0.01; ***P < 0.001, two-way ANOVA). (C and D) Body weight was monitored after the administration of MRTX849 and dasatinib in nude mice for the indicated weeks after MIA PaCa-2/MIA PaCa-2R inoculation. (E) Survival curve of each group [n = 5 mice per group; **P < 0.01 compared with the vehicle; ##P < 0.01 compared with MRTX849 treatment, log-rank (Mantel-Cox) test]. (F) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (25 mg/kg, p.o., twice a week for 6 weeks) and dasatinib (35 mg/kg, p.o., twice a week for 6 weeks) in Calu1/Calu1R xenograft models. (G) Tumor growth was monitored twice per week (n = 8 to 10 tumors). (H) Body weight was monitored after the administration of MRTX849 and dasatinib in nude mice for the indicated weeks after Calu1/Calu1R inoculation. (I) Survival curve of each group [n = 5 mice per group; *P < 0.05, log-rank (Mantel-Cox) test]. (J) Staining of ABCC1, p-ERK1/2, and PCNA in MIA PaCa-2/MIA PaCa-2R xenograft models on day 29. Scale bars, 50 μm. Quantification of immunohistochemistry analysis was performed by calculation using the immunoreactive score (79) (n = 3; *P < 0.05 or **P < 0.01 compared with the vehicle; ##P < 0.01 compared with MRTX849 treatment).](https://figures.cochat.ai/paper-figures/47d10fc9446140a3a70655849c030853/src-kinase-drives-multidrug-resistance-induced-by-kras-g12c-inhibition-figure-6.jpg)



Verification
Claims the paper makes
15 Valid · 2 Not valid · 9 Not checked · 131 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Likewise, small-molecule inhibition of ABCC1 has so far failed in clinical trials, necessitating alternative methods for preventing or attenuating ABCC1 up-regulation (69).”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > DISCUSSION
What the sources say
- Disputedcites [69] K. M. Hanssen, M. Haber, J. I. Fletcher, Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. Drug Resist. Updat. 59, 100795 (2021). 34983733 sourceExperimental — accuracy not yet measured
The Conclusions and future perspectives section (page unavailable) says that P-gp inhibitors failed to improve patient outcomes in clinical trials, dampening enthusiasm for MRP1 inhibition. The small-molecule inhibition discussion describes MRP1 results as preclinical, not as failed ABCC1 clinical trials. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although this is an important milestone in precision oncology, G12Ci treatments are facing challenges due to the emerging development of drug resistance (13, 14).”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > INTRODUCTION
What the sources say
- Supportedcites [13] M. M. Awad, S. Liu, I. I. Rybkin, K. C. Arbour, J. Dilly, V. W. Zhu, M. L. Johnson, R. S. Heist, T. Patil, G. J. Riely, J. O. Jacobson, X. Yang, N. S. Persky, D. E. Root, K. E. Lowder, H. Feng, S. S. Zhang, K. M. Haigis, Y. P. Hung, L. M. Sholl, B. M. Wolpin, J. Wiese, J. Christiansen, J. Lee, A. B. Schrock, L. P. Lim, K. Garg, M. Li, L. D. Engstrom, L. Waters, J. D. Lawson, P. Olson, P. Lito, S. I. Ou, J. G. Christensen, P. A. Janne, A. J. Aguirre, Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382– 2393 (2021). 34161704 PMC8864540 source
The introduction states that acquired resistance to single-agent KRASG12C inhibitors eventually occurred in most patients despite clinical benefit. The Discussion describes multiple mechanisms of resistance and the need for therapies to combat them. (LLM, conf=0.94)
- Supportedcites [14] Y. Zhao, Y. R. Murciano-Goroff, J. Y. Xue, A. Ang, J. Lucas, T. T. Mai, A. F. Da Cruz Paula, A. Y. Saiki, D. Mohn, P. Achanta, A. E. Sisk, K. S. Arora, R. S. Roy, D. Kim, C. Li, L. P. Lim, M. Li, A. Bahr, B. R. Loomis, E. de Stanchina, J. S. Reis-Filho, B. Weigelt, M. Berger, G. Riely, K. C. Arbour, J. R. Lipford, B. T. Li, P. Lito, Diverse alterations associated with resistance to KRASG12C inhibition. Nature 599, 679– 683 (2021). 34759319 PMC8887821 source
The Abstract reports treatment-emergent alterations in patients receiving a KRAS(G12C) inhibitor and describes resistance arising during treatment. It also says this resistance poses a challenge for treating patients who progress on inhibitor monotherapy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This screen identified ABCC1 as a top-ranked gene whose disruption could reverse resistance to the G12Ci AMG510 (Fig. 2F).”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > ABCC1 drives MRTX849-induced drug resistance
What the sources say
- Partly supportedcites [14] Y. Zhao, Y. R. Murciano-Goroff, J. Y. Xue, A. Ang, J. Lucas, T. T. Mai, A. F. Da Cruz Paula, A. Y. Saiki, D. Mohn, P. Achanta, A. E. Sisk, K. S. Arora, R. S. Roy, D. Kim, C. Li, L. P. Lim, M. Li, A. Bahr, B. R. Loomis, E. de Stanchina, J. S. Reis-Filho, B. Weigelt, M. Berger, G. Riely, K. C. Arbour, J. R. Lipford, B. T. Li, P. Lito, Diverse alterations associated with resistance to KRASG12C inhibition. Nature 599, 679– 683 (2021). 34759319 PMC8887821 sourceExperimental — accuracy not yet measured
The Methods (CRISPR-CAS9 functional genetic screen; page unavailable) describe a genome-wide screen comparing resistant R1 cells with parental H358 cells under sotorasib treatment. The reported screen hits include SHOC2 and other ERK-signaling genes, but our copy does not identify ABCC1 as a top-ranked hit or show that its disruption reverses resistance. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through RNA-seq analysis of metastatic tumors in the neck lymph nodes during the AMG510-resistant phase compared to pretreatment lymph node tumors, a GO analysis revealed up-regulation of the ATPase-dependent transporter complex upon acquisition of resistance to AMG510 (Fig. 2B).”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > ABCC1 drives MRTX849-induced drug resistance
What the sources say
- Partly supportedcites [37] Y. S. Tsai, M. G. Woodcock, S. H. Azam, L. B. Thorne, K. L. Kanchi, J. S. Parker, B. G. Vincent, C. V. Pecot, Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. J. Clin. Invest. 132, e155523 (2022). 34990404 PMC8843735 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A genome-wide CRISPR screen revealed that the adenosine triphosphate binding cassette transporter ABCC1 mediates MRTX849 resistance.”
- Also stated in: § ABCC1 drives MRTX849-induced drug resistance · hedged
“This screen identified ABCC1 as a top-ranked gene whose disruption could reverse resistance to the G12Ci AMG510 (Fig. 2F).”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > Abstract
What the sources say
- Partly supportedcites [14] Y. Zhao, Y. R. Murciano-Goroff, J. Y. Xue, A. Ang, J. Lucas, T. T. Mai, A. F. Da Cruz Paula, A. Y. Saiki, D. Mohn, P. Achanta, A. E. Sisk, K. S. Arora, R. S. Roy, D. Kim, C. Li, L. P. Lim, M. Li, A. Bahr, B. R. Loomis, E. de Stanchina, J. S. Reis-Filho, B. Weigelt, M. Berger, G. Riely, K. C. Arbour, J. R. Lipford, B. T. Li, P. Lito, Diverse alterations associated with resistance to KRASG12C inhibition. Nature 599, 679– 683 (2021). 34759319 PMC8887821 sourceExperimental — accuracy not yet measured
The Methods (CRISPR-CAS9 functional genetic screen; page unavailable) describe a genome-wide screen, but it tested sotorasib, not MRTX849. The results passage (labelled Abstract in our copy; page unavailable) identifies ERK-signaling genes including SHOC2 and NRAS; it does not report ABCC1 as a resistance mediator. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § ABCC1 drives MRTX849-induced drug resistance · hedged
88 more claims · 2 with their cited sources checked
Create a free account to see all 157 claims and every source verdict.
- Probably not a substantial claim. 37
- It may state two separate claims as one. 32
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Combining adagrasib with SRC inhibitors (dasatinib, bosutinib) was synergistic in KRAS G12C cancer cells [148].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [148]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to cooperating with FAK, SRC can directly mediate resistance to adagrasib by activating transcription factor JUN [148].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [148]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to RTKs, non-receptor tyrosine kinases such as focal adhesion kinase (FAK) and SRC can promote resistance to KRAS-targeted therapy.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > The anticancer effect of MRTX849 with SRC inhibitors in KRAS-G12C cell-line derived mouse models
“(A) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (35 mg/kg, p.o., oral gavage) and dasatinib (35 mg/kg, oral gavage) in MIA PaCa-2/MIA PaCa-2R xenograft models.”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > MATERIALS AND METHODS > Preclinical models with acquired resistance to G12Ci treatment
“Once tumors were established (around 80 to 100 mm3), mice were randomized into four groups, including ones that received MRTX849 (25 mg/kg) and/or dasatinib (35 mg/kg) twice a week for 3 to 6 weeks by oral gavage.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > The anticancer effect of MRTX849 with SRC inhibitors in KRAS-G12C cell-line derived mouse models
“Furthermore, the combination group exhibited enlarged glomeruli, disorganized renal tubules in the kidneys, and inflammatory infiltration in the pancreas (Fig. 7H).”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > The anticancer effect of MRTX849 with SRC inhibitors in KRAS-G12C cell-line derived mouse models
“(H) Representative images of H&E staining of the liver, lung, pancreas, and spleen from mice bearing mKRC.1 tumors, treated with either vehicle or the combination of MRTX849 and bosutinib.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > ABCC1 up-regulation in MRTX849-resistant cells leads to multidrug resistance
“However, there was no significant difference in the reduction in tumor weight between the combination treatment and gemcitabine alone (Fig. 8I), suggesting that the toxicity was due to gemcitabine.”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > ABCC1 up-regulation in MRTX849-resistant cells leads to multidrug resistance
“(H) Tumor weight on day 42 (n = 5). (I) Body weight was monitored in nude mice for the indicated weeks after MIA PaCa-2/MIA PaCa-2R inoculation (n = 5).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > Reactivation of the MAPK signaling pathway in MRTX849-resistant KRAS-G12C–mutant cells
“The cell colonies were stained with 0.1% crystal violet for evaluation.”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > MATERIALS AND METHODS > Colony formation assay
“Fixed cells were stained with crystal violet (0.05%) for 30 min at room temperature.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > RESULTS > Dasatinib enhances the efficacy of MRTX849 in MRTX849-resistant cells
“across 11 KRAS-G12C–mutant NSCLC cell lines (SW873, H358, HCC44, HCC4019, DFCI024, HCC2122, H1373, H1792, H2030, HOP62, and UM-UC-3)”
§ SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition > MATERIALS AND METHODS > Cell lines and cell culture
“UM-UC-3 (a human urinary bladder carcinoma cell line), PANC1 (a human PDAC cell line), HT1080 (a human fibrosarcoma cell line), and SW873 (a human colorectal carcinoma cell line)”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Cited by
Cytosolic cytochrome c represses ferroptosis
Song, X., Zhou, Z., Liu, J., Li, J., Yu, C., Zeh, H. J., Klionsky, D. J., Stockwell, B. R., Wang, J., Kang, R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.014 · Cited by 66
Self-citationHe, Y., Tu, X., Xue, Y., Chen, Y., Ye, B., Li, X., Li, D., Zhong, Z., & Zhong, Q. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101357 · Cited by 34
“Song et al. [104] identified ATP-binding cassette transporter C1 (ABCC1) as a key gene for MRTX849 resistance in KRAS-G12C mutant non-small cell lung cancer (NSCLC) using CRISPR-Cas9.”
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 9
“This activation can lead to JUN phosphorylation [134].”
Multi-oncogene targeting in cancer therapy: A miRNA-driven pharmacological approach
Salunkhe, S. S., Ghatage, T., & Prabhakar, B. S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117417 · Cited by 12
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Combining adagrasib with SRC inhibitors (dasatinib, bosutinib) was synergistic in KRAS G12C cancer cells [151].”
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7
Self-citationKRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 16
Self-citationPatient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing
Tang, W., & Tian, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1639268 · Cited by 8
Sun, X., Gayathri, S., Kumbier, K., Hammerlindl, H., Ahern, E., Wu, L. F., & Altschuler, S. J. (2026) · Science Advances · doi:10.1126/sciadv.aed7476 · Cited by 1
Vitale, A., Marafioti, M., Galassi, T., Madonia, G., Moro, M., & Dubois, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105396 · Cited by 2
Stickler, S., Eggerstorfer, M.-T., Rieche, M., Arslan, S., Teufelsbauer, M., HOHENEGGER, M., Weigl, L. G., & Hamilton, G. (2026) · Scientific Reports · doi:10.1038/s41598-026-43207-2 · Cited by 3
“Synergy of Bosutinib with KRAS G12C inhibitors was reported, and this drug was found to prevent development of resistance 60 .”
Wang, X., Hong, X., Liu, W., Xu, Y., Chen, R., Chen, F., Wang, K., & Wang, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117766 · Cited by 1
Muhammad, M., Khinji, A. A., Al-Ansari, M., Al-Marri, N., Al-Shaheen, S., & Malouche, D. (2026) · Cancers · doi:10.3390/cancers18193139
Salih, R., Sirajudeen, F., & Rahmani, M. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.030
Salvianolic Acid A Induces Ferroptosis in Non-Small Cell Lung Cancer via the SRC/YAP/GPX4 Axis
Jiang, R., Liu, H., Xiang, H., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146265 · Cited by 1
“Importantly, reduction in SRC expression has been shown to alleviate drug resistance in individuals with NSCLC [22,23].”
Si, W., Zhou, J., & Jiang, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1864153 · Cited by 1
“In addition, through genome-wide CRISPR screening combined with organoid-based functional assays, the ef fl ux transporter ABCC1 was identi fi ed as a critical mediator of resistance to KRAS^G12C inhibitors, and co-treatment with Src inhibitors effectively overcame this resistance barrier (50).”
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
Jain, A., Rosell, R., Dharmashekara, C., Shreevatsa, B., González-Cao, M., Shivakumar, A., Kollur, S. P., Prasad, A., Shivamallu, C., & Prasad, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05533-0
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
Zhu, Y., Zhang, C., Li, M., Ai, L., Xu, F., Yu, Y., Yu, S., Xu, X., Liu, Q., Zhu, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03838-1
Self-citationAdaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
Udagawa, H., Shibata, Y., Nilsson, M. B., Nishii, K., Robichaux, J. P., Galan-Cobo, A., He, J., Poteete, A., Qian, Y., Molkentine, D., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103991 · Cited by 1
Zou, X., Song, P., Song, S., Zhang, G., Wang, X., Yang, T., Zhou, L., & Lin, Y. (2026) · Biomedicines · doi:10.3390/biomedicines14040892 · Cited by 1
“Dasatinib reverses resistance to KRAS-G12C inhibitors and anti-tumor efficacy by inhibiting SRC kinase and blocking JUN-mediated expression of the multidrug resistance protein ABCC1 [52].”
Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane ProtrusionsPreprint
Gihana, G. M., Bhatt, K., Chang, B.-J., Murali, V. S., Zhou, F., Noh, J., Ravishankar, R., Borges, H., Lin, J., Oceguera, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.09.717047
Thielen, N., Wei, N., Nagai, E., Houston, M. A., Augenlicht, L. H., Shin, A. E., Gabre, J. T., Rustgi, A. K., Ha, G., LaFave, L. M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01384-3 · Cited by 1
“Strikingly, our detection of SRC aligns with a recent study that showed the SRC-JUN pathway, activated via RAF1-MEK-ERK and potentiallyJNK,drivesG12Cinhibitorresistance,raisingthepossibilitythat analogousMAPK-dependentmechanismsunderliesG12Dinhibitor resistance 49 .”
Bhandari, K., Lu, M., Marshall, G., Kong, J. S., Xu, C., Jain, A., Huang, Y., Hollingsworth, M. A., & Ding, W. (2025) · The FASEB Journal · doi:10.1096/fj.202500874r
“Furthermore, MRP1 has been shown to mediate drug resistance to a KRAS inhibitor in PDAC cells [40] suggesting the relevance of MRP1 to KRAS-mediated signaling in PDAC cells.”
Thielen, N., Wei, N., Nagai, E., Chu, E., Kitamura, S., & Kuang, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.27.662039
Metadata
- Authors
- Song, X., Zhou, Z., Elmezayen, A., Wu, R., Yu, C., Gao, B., Minna, J. D., Westover, K. D., Zeh, H. J., Kroemer, G., Heasley, L. E., Kang, R., & Tang, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Inserm (FR)
- VA Eastern Colorado Health Care System (US)
- Corresponding author
- Song, Xinxin
- Tang, Daolin
- ORCID
- Venue
- Science Advances
- Published
- 2024-12-13
- Volume
- 10
- Issue
- 50
- Pages
- eadq4274-eadq4274
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC11633746
- OpenAlex
- W4405280443
- Semantic Scholar
- 73cf84601cd445f6b977aa9f10f264a438ee1f0c
- Cited by
- 26
- References
- 86
- Citations by year
- 2026: 18 · 2025: 8
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 BX004751)
- National Cancer Institute (R01CA229275, R01CA244341, R01CA211070, R01CA160417, P50CA070907, U54CA224065, P30CA142543)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- KRAS G12C, adagrasib, Src kinase, multidrug resistance, dasatinib, MRP1, c-Jun, MAPK signaling, covalent KRAS inhibitor, non-small cell lung cancer, pancreatic ductal adenocarcinoma, drug synergy, patient-derived organoids
- MeSH terms
- Dasatinib, Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins c-jun, Drug Resistance, Multiple, Drug Resistance, Neoplasm, src-Family Kinases, Xenograft Model Antitumor Assays, ATP-Binding Cassette, Sub-Family C Proteins, Cell Line, Tumor, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.